Amneal Pharmaceuticals, Inc. (AMRX) stock
AMRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/3072% above fair value
$21.88+0.76 (+3.60%)
Close on Nov 18, 2026Market cap $6.99BP/E 44.7Yield –
Amneal Pharmaceuticals operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Amneal Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was $453.92M, up 20.6% year over year. For fiscal 2025 it was $394.10M, up 58.1% from the year before. The highest annual figure on record is $394.10M in fiscal 2025.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $394.10M | +58.1% |
| FY2024 | Dec 31, 2024 | $249.33M | +22.0% |
| FY2023 | Dec 31, 2023 | $204.37M | – |
| FY2022 | Dec 31, 2022 | -$94.93M | -162.2% |
| FY2021 | Dec 31, 2021 | $152.72M | +67.5% |
| FY2020 | Dec 31, 2020 | $91.16M | – |
| FY2019 | Dec 31, 2019 | -$248.68M | – |
| FY2018 | Dec 31, 2018 | -$19.67M | -108.0% |
| FY2017 | Dec 31, 2017 | $245.10M | -14.0% |
| FY2016 | Dec 31, 2016 | $284.88M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $129.77M | +16.5% |
| Q1 FY2026 | Mar 31, 2026 | $141.77M | +41.3% |
| Q4 FY2025 | Dec 31, 2025 | $112.03M | +47.8% |
| Q3 FY2025 | Sep 30, 2025 | $70.34M | -20.8% |
| Q2 FY2025 | Jun 30, 2025 | $111.37M | +16.7% |
| Q1 FY2025 | Mar 31, 2025 | $100.35M | – |
| Q4 FY2024 | Dec 31, 2024 | $75.79M | +434.0% |
| Q3 FY2024 | Sep 30, 2024 | $88.81M | +17.4% |
| Q2 FY2024 | Jun 30, 2024 | $95.47M | +19.2% |
| Q1 FY2024 | Mar 31, 2024 | -$10.75M | -131.2% |
| Q4 FY2023 | Dec 31, 2023 | $14.19M | -60.6% |
| Q3 FY2023 | Sep 30, 2023 | $75.65M | +70.6% |
| Q2 FY2023 | Jun 30, 2023 | $80.08M | – |
| Q1 FY2023 | Mar 31, 2023 | $34.45M | +47.8% |
| Q4 FY2022 | Dec 31, 2022 | $36.03M | +222.4% |
| Q3 FY2022 | Sep 30, 2022 | $44.35M | +55.5% |
| Q2 FY2022 | Jun 30, 2022 | -$198.62M | -395.9% |
| Q1 FY2022 | Mar 31, 2022 | $23.31M | -49.2% |
| Q4 FY2021 | Dec 31, 2021 | $11.18M | -44.6% |
| Q3 FY2021 | Sep 30, 2021 | $28.52M | +1071.0% |
| Q2 FY2021 | Jun 30, 2021 | $67.12M | +524.3% |
| Q1 FY2021 | Mar 31, 2021 | $45.91M | -20.6% |
| Q4 FY2020 | Dec 31, 2020 | $20.18M | – |
| Q3 FY2020 | Sep 30, 2020 | $2.44M | – |
| Q2 FY2020 | Jun 30, 2020 | $10.75M | – |
| Q1 FY2020 | Mar 31, 2020 | $57.79M | – |
| Q4 FY2019 | Dec 31, 2019 | -$23.14M | -199.4% |
| Q3 FY2019 | Sep 30, 2019 | -$112.27M | -250.6% |
| Q2 FY2019 | Jun 30, 2019 | -$18.91M | – |
| Q1 FY2019 | Mar 31, 2019 | -$94.36M | -248.5% |
| Q4 FY2018 | Dec 31, 2018 | $23.28M | -70.5% |
| Q3 FY2018 | Sep 30, 2018 | $74.56M | -5.3% |
| Q2 FY2018 | Jun 30, 2018 | -$181.06M | -505.9% |
| Q1 FY2018 | Mar 31, 2018 | $63.55M | – |
| Q4 FY2017 | Dec 31, 2017 | $79.02M | – |
| Q3 FY2017 | Sep 30, 2017 | $78.75M | – |
| Q2 FY2017 | Jun 30, 2017 | $44.60M | – |
See a number that looks wrong?